Evidence map›Paper›PMID 42750920›Full record

ArticleNeuro-oncology practice2026

WF-1801: Single-arm pilot study of ramipril for prevention of radiation-induced cognitive decline in glioblastoma patients receiving chemoradiotherapy.

Christina K Cramer, Sydney Smith, Emily V Dressler, Brandi Page, Jeffrey S Wefel, Stephen R Rapp, Edward H Ip, Stephanie L Pugh, Ashley Sumrall, Roy E Strowd and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Christina K CramerDepartment of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.ORCID https://orcid.org/0000-0001-7618-3921
Sydney SmithDepartment of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC, USA.ORCID https://orcid.org/0000-0002-1904-3647
Emily V DresslerDepartment of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC, USA.ORCID https://orcid.org/0000-0002-6054-7839
Brandi PageDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-1770-099X
Jeffrey S WefelDepartment of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0003-3584-023X
Stephen R RappDepartment of Psychiatry and Behavioral Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.ORCID https://orcid.org/0000-0002-9766-3104
Edward H IpDepartment of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC, USA.ORCID https://orcid.org/0000-0002-4811-4205
Stephanie L PughDepartment of Statistics, American College of Radiology, NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA.ORCID https://orcid.org/0000-0002-5977-8912
Ashley SumrallDepartment of Cancer Medicine, Wake Forest University School of Medicine, Charlotte, NC, USA.ORCID https://orcid.org/0000-0002-2863-203X
Roy E StrowdDepartment of Neurology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.ORCID https://orcid.org/0000-0001-6651-5267
Zachary K VaslowDepartment of Neuro-Oncology, Cone Health Cancer Center, Greensboro, NC, USA.ORCID https://orcid.org/0009-0003-4211-7397
Gena Volas-ReddGeorgia Cancer Specialists, Northside Hospital Cancer Institute, Atlanta, GA, USA.ORCID https://orcid.org/0009-0001-2232-9822
Kathryn E WeaverDepartment of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC, USA.ORCID https://orcid.org/0000-0001-9006-4064
Glenn J LesserDepartment of Cancer Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.ORCID https://orcid.org/0009-0003-5471-8907
Michael D ChanDepartment of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.ORCID https://orcid.org/0000-0002-5278-6709

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam · 2014 to 2026
$146.4M
NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
Wake Forest NCORP Research BaseUG1CA189824 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Emily Van Meter Dressler, GLENN J LESSER · 2014 to 2026
$57.9M
NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS UG1 CA189824NCI NIH HHS UG1 CA189867
6 · The paper itself

Abstract

Background: To examine the feasibility of adding ramipril for prevention of cognitive decline to chemoradiation treatment of glioblastoma (GBM). Methods: This prospective single-arm study (WF-1801) coordinated by the Wake Forest NCI Community Oncology Research Program Research Base (UG1CA189824) assessed feasibility, tolerability, and potential efficacy of ramipril to prevent treatment-induced cognitive decline in patients with GBM. Inclusion criteria and chemoradiotherapeutic paradigms were mirrored to the standard arm of NRG/RTOG 0825, such that cognitive outcomes could be compared. All patients were treated with ramipril during chemoradiation and for 4 weeks after completion of radiotherapy (RT). Major outcomes were retention and the Clinical Trial Battery Composite (CTB COMP) score of the cognitive tests. Results were compared to the corresponding outcomes from NRG/RTOG 0825. Results: A total of 75 participants were accrued between March 25, 2019 and November 14, 2023: median age was 63 years. The NRG/RTOG 0825 cohort was younger (median 57 years, Conclusions: The ramipril intervention did not meet the prespecified feasibility endpoint, neither did the cognitive scores differ significantly from the NRG/RTOG 0925 control group. We expect other agents will be the focus of future cytoprotective trials.

Identifiers

PMID42750920
PMCPMC13578509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.